Non-Invasive Prenatal Testing for Fetal Aneuploidy with 22q11.2 Microdeletion
Ordering Recommendation

First- or second-tier screening test for the most common fetal aneuploidy disorders (trisomy 13, trisomy 18, trisomy 21 [Down syndrome], Turner syndrome, sex chromosome aneuploidies [XXX, XXY, XYY], triploidy) and microdeletions causing 22q11.2 deletion (DiGeorge or velocardiofacial [VCFS] syndrome). Testing may be offered to pregnant women with singleton or monozygotic twin pregnancies from 9 weeks 0 days gestation to term. Test is not recommended for women who are carrying dizygotic twins, triplets, or higher-order multiples, who have a known twin demise, who have used an egg donor, who are surrogates not using their own egg, or who have had an allogenic bone marrow transplant. IMPORTANT: Monozygotic twin specimens will be run at Natera and reported through ARUP.

Targeted Sequencing with SNPs
Sun-Sat: Varies
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Whole blood in Cell-Free DNA BCT Tube. All specimens must be collected using the NIPT ANEU kit (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787.
Required Specimen: Maternal specimens must be collected in 2 Cell-Free DNA BCT tubes. 
Specimen Preparation
Transport 20 mL maternal blood in Cell-Free DNA BCT Tube (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. (Min: 16 mL) 
Storage/Transport Temperature
Room temperature. 
Unacceptable Conditions
Patient History for Non-Invasive Prenatal Testing (NIPT) form required. 
Ambient: 5 days; Refrigerated: Unacceptable; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report.

Samples with monozygotic twin pregnancies will be sent to Natera, Inc.

Testing utilizes a single-nucleotide polymorphism (SNP)/informatics-based approach to detect fetal copy number for the five chromosomes responsible for the majority of live-birth aneuploidies (chromosomes 13, 18, 21, X, Y, and triploidy) and certain specific microdeletion syndromes (see current list of microdeletion syndromes listed under "Ordering Recommendations"). This is a screening test to help identify fetuses at risk for Down syndrome, trisomy 18, trisomy 13 and Turner syndrome, as well as fetuses affected with the specified microdeletion syndromes listed. This test should not be considered diagnostic. All positive results should be confirmed by amniocentesis or CVS.
Hotline History
Component Test Code*Component Chart NameLOINC
2008381Trisomy 2173966-4
2008382Trisomy 1873825-2
2008383Trisomy 1373824-5
2008386Monosomy X73821-1
2008430Fetal Fraction
2008431Report Fetal Sex?8251-1
2008830Triploidy/Vanishing Twin
2009259Result Summary48767-8
2009260Gestational Age at draw (Weeks)49051-6
2010002Maternal Weight (Pounds)8338-6
2010003Gestational Age at draw (Days)49052-4
2010004Fetal Sex11882-8
201035422q11.2 deletion syndrome
2013131Maternal Height (Inches)
2013135Number of Fetuses
2013143EER Fetal Aneuploidy w/22q11.2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please view this test within the Laboratory Test Directory found at
  • 22q
  • 45X
  • cell free
  • cell-free
  • cellfree
  • cfDNA
  • cffDNA
  • DiGeroge
  • edward syndrome
  • Natera
  • NIPD
  • Panorama
  • patau syndrome
  • T13
  • T18
  • trisomy 21